ANRO · Alto Neuroscience, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-27 | Miller Andrew Craig |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the Reporting Person did not pay any consideration for the derivative securities. The shares underlying the option shall vest in 36 equal monthly installments commencing on June 27, 2026, subject to the Reporting Person's continuous service through each vesting date. |
Stock Option (right to buy)
|
26,000 |
| 2026-05-27 | Miller Andrew Craig |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-05-14 | Etkin Amit |
Director, PRESIDENT AND CEO |
Gift↓
Filing footnotes — Common Stock (Direct)
The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust. |
Common Stock
|
400,000 |
| 2026-05-12 | Cox Christopher Nixon |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (right to buy)
|
10,958 |
| 2026-05-12 | Sanchez Ramiro |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (right to buy)
|
10,958 |
| 2026-05-12 | Manji Husseini |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (right to buy)
|
10,958 |
| 2026-05-12 | York Gwill |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (right to buy)
|
10,958 |
| 2026-05-12 | Dreyfus Andrew |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Stock Option (right to buy)
|
10,958 |
| 2026-03-01 | Etkin Amit |
Director, PRESIDENT AND CEO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person. |
Common Stock
|
6,227 |
| 2026-03-01 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person. |
Common Stock
|
2,806 |
| 2026-02-11 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
124,000 |
| 2026-02-11 | Etkin Amit |
Director, PRESIDENT AND CEO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
306,000 |
| 2026-02-11 | Hanley Jr. Michael Conick |
Chief Business Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
131,000 |
| 2026-02-11 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
200,000 |
| 2026-01-02 | Manji Husseini |
Director |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
1,057 shares underlying the option shall vest on each of March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $50,000. |
Employee Stock Option (right to buy)
|
4,228 |
| 2026-01-02 | Cox Christopher Nixon |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000. 1,797 shares underlying the option shall vest on March 31, 2026, 1,797 shares underlying the option shall vest on June 30, 2026, 1,798 shares underlying the option shall vest on September 30, 2026 and 1,797 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
Stock Option (right to buy)
|
7,189 |
| 2026-01-02 | York Gwill |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $62,000. 1,311 shares underlying the option shall vest on March 31, 2026, 1,311 shares underlying the option shall vest on June 30, 2026, 1,310 shares underlying the option shall vest on September 30, 2026 and 1,311 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
Stock Option (right to buy)
|
5,243 |
| 2026-01-02 | Sanchez Ramiro |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000. 952 shares underlying the option shall vest on March 31, 2026, 951 shares underlying the option shall vest on June 30, 2026, 952 shares underlying the option shall vest on September 30, 2026 and 951 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
Stock Option (right to buy)
|
3,806 |
| 2025-08-12 | Sanchez Ramiro |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $8,682.07. 1,383 shares underlying the option shall vest on September 30, 2025, and 2,545 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date. |
Stock Option (right to buy)
|
3,928 |
| 2025-08-12 | Sanchez Ramiro |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. The shares underlying the option shall vest in 36 equal monthly installments commencing on September 12, 2025, subject to the Reporting Person's continuous service through each vesting date. |
Stock Option (right to buy)
|
30,574 |
| 2025-08-12 | Sanchez Ramiro |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date |
Employee Stock Option (Right to Buy)
|
247,290 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
76,000 |
| 2025-07-03 | Hanley Jr. Michael Conick |
Chief Business Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
125,000 |
| 2025-07-03 | Hanley Jr. Michael Conick |
Chief Business Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. The shares subject to the option are fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
8,000 |
| 2025-07-03 | Hanley Jr. Michael Conick |
Chief Business Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
125,000 |
| 2025-07-03 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date. |
Employee Stock Option (Right to Buy)
|
202,329 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
215,000 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
33,008 |
| 2025-07-03 | Hanley Jr. Michael Conick |
Chief Business Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. The shares subject to the option are fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
8,000 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
73,000 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
123,645 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
223,000 |
| 2025-07-03 | Hanley Jr. Michael Conick |
Chief Business Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
188,000 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
215,000 |
| 2025-07-03 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
90,000 |
| 2025-07-03 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date. |
Employee Stock Option (Right to Buy)
|
44,962 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
123,645 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
73,000 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
33,008 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
34,620 |
| 2025-07-03 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
135,000 |
| 2025-07-03 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date. |
Employee Stock Option (Right to Buy)
|
44,962 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
223,000 |
| 2025-07-03 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
33,833 |
| 2025-07-03 | Smith Nicholas Conrad |
CHIEF FINANCIAL OFFICER & CBO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
33,833 |
| 2025-07-03 | Hanley Jr. Michael Conick |
Chief Business Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
188,000 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Employee Stock Option (Right to Buy)
|
34,620 |
| 2025-07-03 | Etkin Amit |
Director, PRESIDENT AND CEO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date |
Employee Stock Option (Right to Buy)
|
247,290 |
| 2025-07-03 | Savitz Adam |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. The shares subject to the option are fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
22,481 |